Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

NCT07687706 is registered in ClinicalTrials.gov with Hanyang University Guri Hospital as lead sponsor.

NCT NCT07687706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07687706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
Lead sponsor
Hanyang University Guri Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
January 26, 2026
Completion date
December 31, 2027
Enrollment
1,524 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrovascular disease, gastrointestinal bleeding, gastrointestinal complication, ischemic stroke, ischemic stroke, acute, transient ischemic attack (tia)